Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Hutchmed

Evaluate

June 27, 2023

More details needed on Sanofi’s atopic dermatitis win

The anti-Ox40 ligand antibody amlitelimab could have its work cut out to best the company’s own Dupixent.

Thumbnail
June 04, 2023

Asco 2023 – liver tox casts a pall over Servier’s Indigo readout

Vorasidenib, potentially the first targeted therapy for low-grade glioma, comes at a toxicity price.

Article image
Vantage logo
March 23, 2023

Lazertinib and Tagrisso go head to head

A key test of J&J’s targeted agent approaches, but Astra has a trick up its sleeve that could render this readout irrelevant.

Article image
Vantage logo
January 26, 2023

US regulator stays firm on knockbacks

Article image
Vantage logo
January 23, 2023

The world's twelfth VEGF drug will be sold by Takeda

The Japanese company keeps the licensing fires burning with a $400m deal for Hutchmed’s fruquintinib.

Article image
Vantage logo
August 03, 2022

Rigel makes Forma wait for olutasidenib payday

Article image
Vantage logo
May 04, 2022

US FDA approval tracker: April 2022

Article image
Vantage logo
May 03, 2022

China-backed US approvals continue to hang in the balance

Article image
Vantage logo
April 22, 2022

What next for developers seeking to emulate Zydelig?

Article image
Vantage logo
April 20, 2022

First-quarter biotech risers work hard for the win

Amid a difficult start to the year for the drug development sector, Abbvie, Bayer, Ipsen and Lantheus stand out as stock market gainers.

Article image
Vantage logo
April 04, 2022

Swift resolution emerges to China's non-compliance

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up